Real-World Evaluation of the Immune Checkpoint Inhibitor Score (IChIS) in Advanced Non-Small Cell Lung Cancer Treated with Immunotherapy
Higher IChIS was independently associated with shorter PFS in patients with advanced NSCLC receiving ICIs, supporting its potential role as a simple and readily available prognostic biomarker.